Drug Companies Spend $11 Million on Medical Science Liaisons in the United States

New Cutting Edge Information study shows highest MSL budget in top commercial market

Drug Companies Spend $11 Million on Medical Science Liaisons in the United States

<0> Cutting Edge InformationCassie Demeter, 919-403-6583 </0>

The highest spending on Medical Science Liaisons (MSLs) occurs in the top markets, with $11.6 million spent on MSLs in the United States, according to a new study published by Cutting Edge Information.

The study, “Managing Medical Science Liaison Teams: Budget, Staffing and Compensation Benchmarks,” shows that the in the US is far ahead of the next highest budget in Japan at roughly $3.2 million. Total budgets for MSLs in countries outside the US ranged from $110,000 to $3.2 million in most markets. However, new and upcoming regulations in Germany and the United Kingdom are likely to cause a decrease in MSL budgets in these two markets, currently at $2.7 million and $1.9 million, respectively.

In recent years, pharmaceutical companies have been shifting spending on MSLs to emerging markets. Larger field-based teams will more quickly develop these territories, especially where companies have already established commercial or . This shift in resources will help develop growth in these emerging markets, especially in India, Russia, and South Korea, where less than $200,000 is dedicated to MSL spending.

“The lower levels of wealth in these countries are outweighed by the vast untapped market of citizens in need of advanced healthcare,” said Elio Evangelista, director of operations at Cutting Edge Information. “Engagement with these physicians by MSLs will help to build interest in more expensive but more effective therapies.”

“Managing Medical Science Liaison Teams: Budget, Staffing and Compensation Benchmarks() includes detailed data on MSL team budgets, headcounts, structures and compensation packages for liaisons located in the US, Europe, Asia and Latin America. The study is designed to help MSL managers and organizations:

For more information about , contact Elio Evangelista at 919-403-6583.

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.